The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 351:2879 December 30, 2004 Number 27
NextNext

Peginterferon and Lamivudine for Hepatitis B

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Marcellin, P.
-PubMed Citation
To the Editor: Marcellin and colleagues (Sept. 16 issue)1 report that patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B had higher rates of a sustained response to treatment with peginterferon alfa-2a than with lamivudine.1 HBeAg-negative chronic hepatitis B is usually associated with precore mutations,2 but it may also develop in patients infected with wild-type strains, with mutations in the basic core promoter.3 Whether these two groups of patients with HBeAg-negative chronic hepatitis differ in their responses to therapy is not known. The study by Marcellin et al. would have been more informative if hepatitis B virus (HBV) genome . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.